Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08057418 · 1 trial · 1 indication
Assessment of TEAEs, SAEs, clinical laboratory values, vital signs, continuous cardiac monitoring and 12-lead ECGs
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will receive single oral solution or tablet dose(s) of placebo. |
| PF-08057418 | EXPERIMENTAL | Participants will receive single oral solution or tablet dose(s) of PF-08057418 |
| Name | Type | Description |
|---|---|---|
| PF-08057418 | DRUG | solution or tablet (fasted/fed) |
| Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.) | OTHER | solution or tablet (fasted/fed) |
Inclusion Criteria: * Adults 18 to 60 years of age (or the minimum age of consent per local regulations) at screening. * Healthy participants, as determined by medical history, physical examination, clinical laboratory tests, and cardiac monitoring. * Body mass index (BMI) between 16 and 32 kg/m² a...
PF-08057418 is an investigational small molecule drug being developed by Pfizer, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific disease or condition it is intended to treat has not been publicly disclosed.
PF-08057418 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States.
PF-08057418 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials of PF-08057418 are currently listed.
PF-08057418 has been evaluated in one Phase 1 trial, NCT07575906, titled a study to learn how a single dose of the study medicine called PF-08057418 is tolerated in the body of healthy adults. The trial was completed, enrolled 8 participants, and was conducted in the United States.
The Phase 1 trial of PF-08057418, NCT07575906, was a randomized, double-blind, placebo-controlled study. It enrolled 8 healthy adult volunteers aged 18 years and older in the United States and evaluated how a single dose of the study medicine was tolerated.